Status:
TERMINATED
Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis
Lead Sponsor:
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Collaborating Sponsors:
Texas Tech University Health Sciences Center
Conditions:
Pulmonary Disease, Chronic Obstructive
Pulmonary Fibrosis
Eligibility:
All Genders
40+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether lozenges containing interferon-alpha can reduce the frequency and severity of coughing in patients with chronic obstructive pulmonary disease (COPD) a...
Detailed Description
Both chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) frequently lead to a chronic cough that negatively impacts the quality of life (QOL) for patients and those ar...
Eligibility Criteria
Inclusion
- For all patients
- history of clinically significant chronic cough for \> 3 months
- For COPD patients
- \>40 years of age
- 20-pack-year history of smoking
- GOLD classification of Stage 1 or higher
- For IPF patients
- \> 50 years of age
- history of unexplained dyspnea on exertion of \> 3 months
- exhibits coughing and bilateral, basilar, inspiratory crackles on physical exam
- presents as being in a stable phase of IPF
- lung biopsy or HRCT indicative of IPF
Exclusion
- ACE inhibitor use
- GERD
- current cancer or history of lung cancer
- non-ambulatory
- hospitalized in the previous 12 months for heart failure
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT00690885
Start Date
June 1 2008
End Date
April 1 2012
Last Update
April 24 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Texas Tech University Health Sciences Center
Lubbock, Texas, United States, 79430